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CHAPTER I 
INTRODUCTION 
Over the decades, the food industry has faced repeated challenges with respect to 
food safety from a variety of sources including new and emerging pathogens that can 
pose serious threats to human health worldwide. The meat industry, especially the beef 
industry, has been especially vulnerable in this regard. Bovine Spongiform 
Encephalopathy (BSE) is one of the most recent and most fatal diseases that has affected 
the food industry, adversely. The first confirmed case of BSE, commonly known as mad 
cow disease in the United States, was reported in December 2003 in a Washington State 
dairy cow. This led to large scale culling of cow herds and bans on meat products that led 
to billions of dollars in economic loss. 
 Bovine Spongiform Encephalopathy belongs to a class of fatal neurodegenerative 
disorders called transmissible spongiform encephalopathy (TSE). These diseases affect 
both humans and animals and are caused by a unique group of infectious agents known as 
PRIONS (Prusiner, 1991a). Prions, unlike bacteria or other infectious agents, are 
glycoproteins that are highly expressed in neuronal cells (Thuring et al., 2002). There are 
several other prion diseases which affect a variety of hosts like Scrapie in sheep and 
goats, Creutzfedlt Jakob disease (CJD), kuru, Grestmann-Straussler syndrome (GSS) and 
fatal insominia (FFI) in humans and encephalopathies in elk, deer, mule, cat and mink 
(Gajdusek, 1977, Masters et al., 1981, Medori et al., 1992).  
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The pathogenesis of prion diseases is a major area of research due to its impact on 
human health and due to the unique biochemical characteristics of prions (Harris, 1999). 
Over the last quarter of the twentieth century, a new variant of the Creutzfeldt-Jakob’s 
disease that affects humans (vCJD), has been identified which has claimed more than 250 
victims worldwide. This disease was transmitted to humans through meat that contained 
prion infected gonadotrophins (Aguzzi et al., 2008). The United States government has 
taken necessary steps not only to prevent the transmission of the Specified Risk Materials 
(SRM) to the human food supply but also to control the transmission of the disease from 
animal to animal (Brown et al., 2003).  
Development of new detection methods and inactivation techniques to control the 
incidence of BSE in human food supply is gaining serious attention. In order to 
accomplish this aim, an in-depth understanding of the biochemical structure and 
processes underlying the conversion of normal prion protein (PrPC) to abnormal prion 
protein (PrPSc) is of paramount importance. Therefore, apart from the availability of the 
abnormal form of prions, the availability of normal prions is also very important in 
conducting these studies. A major difficulty in prion research is the lack of availability of 
the PrPC in sufficient amounts to conduct experiments. Efforts to purify PrPC from 
multiple tissue sources have always met with minimum success. It has always been 
extremely difficult to obtain large amounts of the protein (Mehlhorn et al., 1996). 
Scientists have produced the normal PrPC of different species in various expression 
systems like virus and bacteria. They all faced problems in expressing and purifying the 
recombinant PrPC due to the instability of the protein (Baron et al., 1999). Scientists have 
successfully expressed the PrPC in E.coli using the amino terminal fusion with 
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glutathione-S-transferase or GST and carboxy terminal fusion with hexa histidine 
sequence (Baron et al., 1999). Previous research in our laboratory has also expressed 
PrPC in a bacterial expression system. But expression of a protein like PrPC which might 
need post translational modifications, in a bacterial system might not fully represent the 
actual protein in its structural entirety in vivo. A better approach would be to express and 
purify it in a mammalian system.  Expression of PrPC from scrapie susceptible sheep in a 
mammalian expression system and subsequent purification from it has not been done yet.   
Scrapie is the encephalopathy that affects goats and sheep. We chose to work with 
the normal sheep prion protein for the expression studies for the following reasons: (i) 
Sheep prion protein is one of the most extensively studied and well understood among the 
prion proteins, and (ii) the sheep prion protein sequence differs from the human prion 
protein, implying a barrier for the transmission of Scrapie to humans. The objectives of 
this study are to overexpress the sheep normal prion protein as a fusion with the carboxy 
terminal hexa histidine tag using a mammalian tissue system and purify the protein using 
a Nikel affinity column chromatography. The mammalian cell culture system used to 
overexpress the prion protein was the Human neuroblastoma cells. The expressed protein 
was detected and confirmed using Western Blot assay. 
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CHAPTER II 
REVIEW OF LITERATURE 
2.1 Prions: Overview 
Prions are a group of infectious proteins that were discovered in 1991 by Dr 
Stanely B Prusiner. This discovery added a new and fatal disease causing entity to the list 
of infectious agents and has opened up a new frontier in infectious agent’s research. 
Prions lead to fatal and irreversible neurodegenerative diseases that affect both humans 
and animals. Prions exist in two forms:  normal and abnormal. The abnormal form is the 
infectious protein. The prion diseases are characterized and even identified by the 
intracerebral accumulation of the abnormal form of prions called PrPSc. The amino acid 
sequence of the abnormal isoform is identical to the normal, but PrPSc differs from PrPC 
biochemically (Satoh and Yamamura, 2004). 
Prions are highly resistant to physical and chemical treatments and have more 
similar properties to proteins than to viruses as they are too small (50-150 kDa) to be a 
virus (Alper et al., 1966). The anonymity of prions was resolved by Prusiner who 
conducted enzymatic studies on both physical and biochemical aspects of the scrapie 
infectious agent. Prusiner coin the term prion (pronounced as pree-on) which was derived 
from proteinaceous and infectious, as they were diverse from plasmids, virus and viriods. 
From his experiments he concluded that the scrapie agent did not have any effect on the 
modification or destruction of nucleic acids and the procedures that were involved in the 
destruction or modification of inactivating proteins (Prusiner, 1982).   
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PrPC is a glycosylphosphatidylinositol (GPI) - anchored glycoprotein which is 
primarily expressed in neuronal cells. These proteins are also produced by astrocytes, 
oligodendrocyte, cells in lymphoreticular system (LRS) and follicular dendritic cells 
(FDCs) (Crozet et al., 2007). The major functions of normal prions include cell signaling, 
survival, adhesion and differentiation. Studies have shown PrPC induces polarization in 
the synapse development and also in neuritogenesis (Steele et al., 2006). Apart from the 
neuronal cells, glial cells are also capable of expressing the prions and these proteins are 
accumulated in the cytosol and cell surface membrane (Kikuchi et al., 2004). The prion 
protein is anchored to the cell surface by a GPI molecule.  The C or N terminus 
associated membrane isoforms are located in the endoplasmic reticulum (Nieznanski et 
al., 2005). The process of conversion of the normal form of prion protein to its infectious 
form is by post translational modifications causing changes in protein structures (Stahl et 
al., 1993). It has been reported that mammalian PrPC has two N glycosylation sites which 
appear as bi, uni or unglycosylated forms. Variabilities in structure are results from the 
attachment of both the N-glycans and GPI anchors. The post translational modifications 
(PTM) were found to have a higher impact on the variability in the prion protein 
structure. The exact role and mechanism of this is not known. Many scientists consider N 
glycosylation as the key to the conversion of PrPC to PrPSc. Heterogeneity is thought to 
play a major role in determing the degree and severity of pathogenesis of Transmissible 
Spongiform Encephalopathies (Nieznanski et al., 2005). 
   Prusiner in 1991 found that knockout mice with deficient prion gene (prnp0/0) 
are resistant to the prion diseases. Bioassays of the brain extracts were conducted and 
found that there is no infectivity in the brains of prnp0/0 mice. Studies in transgenic mice 
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indicated that the normal and abnormal forms of the prion protein play a crucial role in 
the pathogenesis and transmission of prion diseases (Prusiner, 1991b). 
2.2 Terminology 
Creutzfeldt-Jacob disease 
 Creutzfeldt - Jakob disease or CJD is the most common neurodegenerative 
disease in humans caused by prions. Patients with CJD show progressive dementia with 
myoclonus, and is diagnosed by Electroencecephalogram (ECG). This eventually leads to 
memory loss and death of the patient (Johnson and Gibbs, 1998). Incidence of CJD 
occurs at the rate of one in million people annually and the average age for the onset of 
the disease is found to be 60-65 years (Collinge and Rossor, 1996). 
Gene 
 A gene is the fundamental functional and physical unit of heredity, composed of 
an ordered sequence of nucleotides positioned on a particular chromosome which 
encodes a specific functional product (Human Genome Project, 2003) 
Glycosylphosphatidiyl Inositol (GPI) 
 Glycosyphophatidyl inosotol is a glycolipid which will get attached to the C-
terminus of the protein during post translational modification (Prusiner, 1991a).  
Meat and Bone Meal (MBM) 
 Meat and Bone Meal is a rendered product which contains 50% of mammalian 
protein used in animal feed to improve the amino acid profile of the feed (Adedokun and 
Adeola, 2005). It does not conatin any blood meal or other animal by-products. The 
United Kingdom posed a ban on the use of MBM in the year 1998, due to the incidence 
of BSE in cattle (Taylor et al., 1994).   
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Open Reading Frame (ORF) 
An open reading frame is a section of an organism’s genome which potentially 
encodes for a protein or poly peptide (Collinge and Rossor, 1996). ORFs are located 
between a start or initiation codon (Methionine) and a stop or termination codon.  
Plasmid 
 Plasmid is an extrachromosomal DNA which is capable of self replicating if in a 
suitable host. It is composed of circular DNA molecules different from the normal 
bacterial genome that are not essential for cell survival (Human Genome Project, 2003). 
They are generally found in bacteria and vary in size from 1 – 200 kilo base pairs 
(Holmgren and Lefers, 2004).  
Prion protein 
 Prion proteins are glycoproteins that are resistant to proteases. They were first 
identified from Syrian Hamaster brain enriched for Scrapie infectivity and is designated 
as PrP 27-30. The prion protein exists in two forms. The normal cellular isoform and is 
about 33-35kDa where as the abnormal isoform is 27-30kDa (Prusiner and McKinley, 
1987). 
Prion protein gene 
The prion protein gene has been identified in a variety of organisms including 
humans (Chesebro et al., 1985). The prion gene is designated as prnp.  
Post translational modification (PTM)  
The chemical modification occurring in a protein after its translation is called a 
post translational modification. It involves addition of various chemicals like glycosyl 
groups, phosphate groups, etc (Polevoda and Sherman, 2003).  
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Scrapie 
 Scrapie is the transmissible spongiform encephalopathy disease affecting goats 
and sheep caused by the infectious agent prions. Scrapie is also charatcterized by its long 
incubation periods and includes ataxia and pruritis. Like other prion infections, Scrapie 
also leads to death of the animal (Prusiner, 1991a). 
Specified Risk Materials (SRM) 
 Specified Risk Materials are the BSE-infected tissues in cattle that have shown to 
have the infectious agent. Tonsils and distal ileum of the small intestine are the SRMs in 
cattle (Turk et al., 1988).  
Transformation 
 Transformation is the process of introduction of an exogenous DNA into a cell, 
causing it to acquire a new phenotype.  
Variant Creutzfeldt-Jacob disease (vCJD) 
 In the year 1994, the United Kingdom saw the incidence of a new form of 
Creutzfeldt-Jacob disease which had distinctive characteristics from the classical CJD. 
The prions identified in BSE and vCJD have the same physical and chemical 
characteristics, which indicates that they have common sources. For this reason, it was 
believed that vCJD is caused by infected beef products (Hill et al., 1997).  
Vector 
A vector is a DNA molecule that replicates autonomously in the host cell, to 
which a segment of the DNA may be attached for replication.  
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Viriod 
Viriods are short infectious pathogens composed of low molecular weight RNA. 
They are so far found only in plants and are capable of using the host’s enzymatic 
machinery for its replication (Prusiner, 1994). 
Virus 
Viruses are small infectious agents composed of one or more nucleic acids and 
are coated with a protein. Some are found to be coated with lipids and carbohydrates. 
Viruses replicate by its nucleic acid using the host’s enzymatic machinery (Prusiner and 
McKinley, 1987). 
2.3 Scrapie 
Natural TSE in sheep is termed as Scrapie. The complete ovine prion gene has 
been characterized and is found to localize in chromosome 13q17/q18. There are three 
exons identified for the gene, and the complete ORF for prion protein is encoded in the 
third exon (O'Neill et al., 2003, Weissmann and Flechsig, 2003). Similar structures in 
prion gene were identified in mouse, cattle and rats. Several polymorphisms associated 
with the prion protein genes were characterized. They are thought to play a role in disease 
susceptibility and are mostly seen in codons 136, 154 and 171(O'Neill et al., 2003). 
Scrapie has been identified as a slow progressive neurologic disorder which has 
been affecting sheep and goats for several years. The disease has long incubation periods 
and exists in different forms in different mammals.  The abnormal isoform of scrapie 
infectious agent when composed of the single glycosylated protein has a molecular 
weight of 27-30 kDa. The molecular weight of the native form is 35-37 kDa (Aiken and 
Marsh, 1990). Scrapie was first diagnosed in the United States in 1947 in a flock of sheep 
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in Michigan. The genetic makeup of the animal also has high impact on the development 
of disease. The susceptibility for the disease can be predicted, if the gene sequence of the 
individual animal is identified. This is because the prion protein gene exhibits mutations 
in three different codons in the ORF at codons 136, 154 and 171 (Aiken and Marsh, 
1990). In United States, mutations in codon 171 are thought to cause the Scrapie 
infection. The animal is highly susceptible to develop Scrapie if the codon 171 
corresponds to the amino acid glutamine (Caughey et al., 1991).  
Scrapie is a disease which has no treatment, and is fatal. Early symptoms of 
Scrapie include weight loss and behavioral changes in animal. Clinical signs of infection 
appear only after 2 to 5 years after the animal was infected (O'Rourke et al., 2000).  The 
spread of the disease can be through vertical transmission (i.e. from mother to off-
springs) and by horizontal transmission (i.e. by environmental factors). There is no 
evidence of any live animal test to detect the presence of the infectious PrPSc and it takes 
several months to years for the symptoms to appear and this depends on the strain of 
scrapie infectious agent.  
2.4 Chemical properties of PrP and recombinant PrP 
The prion protein gene is approximately 256 amino acids long, and has N and C 
terminal signal peptides that are 24-AA and 22-AA respectively. As stated earlier the 
prnp gene is encoded by a single exon (Riesner, 2003). It was found that after proteolysis 
of the abnormal prion protein, the amino terminus gets truncated to form PrP 27-30, 
which is composed of around 142 amino acid sequences (Prusiner, 1982).  
During the trafficking of the protein out of the cell once it is formed, the signal 
peptide which is 1-22 amino acids long gets cleaved and a glycosyl-phosphatidylinosotol 
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(GPI) anchor is added on the cell surface (Turk et al., 1988). The asparagine residues at 
181 and 197 have highly branched glycosylation with the sialic acid substitution. This 
can be visualized on a Western blot assay followed by SDS-PAGE separation of prion 
protein. Three forms of glycosylation can be observed based on the glycosylation pattern 
- with two glycosyl groups, one glycosyl group and with no glycosyl group (Turk et al., 
1988, Prusiner, 1991b).  
The complete coding region of the sheep (Ovis aries) prnp gene is shown in 
Appendix 9. The translation product is a 256 amino acid peptide with both N and C 
terminal signal peptides. The C terminal signal peptide will later be replaced by the GPI 
anchor. The final processed form of prion protein will thereby contain amino acids from 
23-231 (Riesner, 2003). 
2.5 Prions protein genetics and expression 
2.5.1 Prion protein gene structure 
The prion gene that codes for the prion protein is found to be present in all 
mammals and is highly conserved among species (van Rheede et al., 2003). The entire 
ORF of the prion gene is present as a single exon, which is similar to mouse and hamster 
prion gene (Saeki et al., 1996).  The human and mouse prion protein is located in the 
locus 2 and 20 on the chromosome where as the rat prion protein is on chromosome 3 
(Saeki et al., 1996).  In case of eukaryotes, the presence of TATA box (Goldberg-
Hogness box) helps the promoter to bind to RNA polymerase and start transcription. A 
comparison study of mouse prion protein and Syrian Hamster prion protein found that 
they are rich in G+C content in the promoter regions and both lack the TATA box. In this 
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case, these G+C regions may serve as a binding site for the polymerase and the 
transcription factor Sp1 (Basler et al., 1986).  
The prion gene ORFs for many mammals and other organisms have been 
sequenced and they all encode for a protein of ~250 amino acids (Kretzschmar et al., 
1986). Prusiner in 1989 found that the C terminal region of the prion gene ORFs codes 
for a hydrophobic peptide which is later anchored by a GPI and the N terminal has a 
glycine rich region. The C terminus has two consensus sites for glycosylation of cysteines 
and asparagines.  
2.5.2 Prion protein expression in eukaryotic cells 
The mRNA of PrPC is highly expressed in the brain and in other cell types of all 
mammals (Basler et al., 1986). It was found that during the developmental stages of the 
disease, the prion gene mRNA and choline acetyl transferase levels are increased. Also in 
some parts of the brain the PrPC levels are increased during early stages (Basler et al., 
1986). 
The level of expression of the PrPC in brain can be determined by 
Immunohistochemical studies. Immunostaining of PrPC in the Syrian Hamster brain 
showed that the prion protein was largely present in the amygalda region where as the 
expression of PrPSc was much lower. Similar patterns were observed in the other regions 
of brain like stratum radiatum and stratum oriens of the hippocampus.  
The normal scrapie prion protein is protease sensitive and acts as a template for 
the infectious agent in the conversion process from PrPC to PrPSc. It is known that the 
conversion of PrPC to PrPSc is due to the post translational modification and this occurs 
several hours after the mature PrPSc is formed (Borchelt et al., 1990). In most cases of 
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prion diseases, the route of infection is through peripheral infection. Current evidence 
suggests that the neuro invasion and prion replication involves the lymphoid and 
peripheral nervous system. In a study which used transgenic mice for expression of ovine 
prion protein with a neuron specific enolase promoter, it was seen that the protein was 
expressed only in the brains of mice and not in any non-nervous tissues. The use of 
neuron specific promoters helps in the suitable detection of scrapie infectious agent and 
also to study the trafficking of the infectious agent between intracerebral and 
extracerebral compartments. Also the use of neuron specific enolase promoter helps in 
expression of only the infectious form of prion that helps in its specific detection (Crozet 
et al., 2007). 
Not many studies have been conducted that resulted in the successful production 
of normal scrapie prion protein using human cell lines. Several cell lines are known to 
expresses the infectious form of scrapie prion protein like mouse neuroblastoma cells, 
mouse hypothalamic neuronal cells, mouse schwann cells and rat pheochromocytoma 
cells. These cell lines were used to identify the conversion mechanism and sub cellular 
localization of the protease resistant scrapie prion protein. The T98G (Human 
glioblastoma cells) cells expresses the normal prion protein mRNA and produces a high 
level of PrPC in G1 phase. Another study successfully found out that the T98G cells can 
convert the normal prion to abnormal form after reaching a high passage number. The 
conversion took place at the cell surface or in endocytic cellular compartments (Kikuchi 
et al., 2004). 
Infectious prions induce neurotoxicity in the brain cells as a result of 
mitochondrial dysfunction or alteration of inflammatory responses. This leads to 
14 
activation of microglial cells and release of cytokines. It was reported that the PrPSc 106-
126 induces neuronal death, even in the absence of microglia. The expression of the PrPC 
was high during the neuronal differentiation process both in in vitro and in vivo studies. 
In in vivo studies, PrPC is found at a higher amount in mature neurons (Steele et al., 
2006).  
Cell lines expressing larger amounts of normal prion protein are important for 
biochemical studies of both PrPC and PrPSc as theoretically PrPC plays a role in the 
conversion reaction (Sakudo et al., 2008). One of the major concerns using the E.coli 
expression systems, is the production of misfolded or inactive proteins due to high 
expression of the gene and lack of post translational modifications. Initial attempts to 
produce the prion protein using E.coli yielded very low expression levels due to the 
insoluble and unstable nature of the protein. Also attempts to fuse the prions with 
proteins to express in the periplasm were ineffective in producing larger amounts 
(Riesner, 2003). 
2.6 Conversion reaction in prion protein 
The abnormal form of the prion protein, PrPSc, is present in the cell membrane 
and is attached by a GPI anchor (Stahl et al., 1993). The PrPC and PrPSc are chemically 
similar but differ in their structural conformation. Even though they are coded by the 
same gene, due to the post translational modifications in PrPC they exhibit different 
physiochemical properties (Basler et al., 1986). The conversion of normal prion protein 
to abnormal form paved the way for studies involving detection of the causative agent for 
TSEs (Pan et al., 1993). The typical characteristics of prion diseases are the accumulation 
of the PrPSc in the brain (Basler et al., 1986). PrPC has a high alpha helical structure of 
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42% and a very low beta sheet content where as in PrPSc has 21% alpha helix and 54% 
beta sheets (Appendix 8) (Pan et al., 1993).  
There were two models hypothesized so far to explain the conversion of PrPC to 
PrPSc: (i) The ‘refolding’ model or the template assistance model and (ii) the ‘seeding’ or 
the nucleation-polymerization model (Aguzzi and Heppner, 2000). The refolding model 
suggests that a high activation energy barrier spontaneously prevents the conversion of 
PrPC to PrPSc at detectable levels. The seeding model states that the two isoforms are in 
equilibrium strongly favoring the normal PrPC (Telling et al., 1995). An aggregate will be 
formed by the coupling of PrPC with PrPSc and hence acts as a seed for nuclear-
polymerization reaction (Jarrett and Lansbury, 1993).  
2.7 Detection of prion protein 
2.7.1 Introduction 
Prusiner in 1982 coined the term Prions. He derived it from coupling 
proteineceous infectious as these proteins caused transmissible diseases when the normal 
form of prion is converted to the abnormal protein. This protein only hypothesis was 
widely accepted by the scientific community, even though there is no direct or pure 
evidence available yet (Chesebro, 2003). Several studies have revealed that both the PrPC 
and the PrPSc are glycoproteins and the PrPSc is anchored to the cell membrane by a GPI. 
Both these isoforms are approximately 35kDa in molecular weight (Stahl et al., 1993). 
The detection of prion proteins are of high priority in identifying the transmissible 
spongiform encephalopathies. The major site of infection not only in case of scrapie but 
in all major TSE’s is the CNS (Aguzzi and Heppner, 2000).  
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2.7.2 Immuno-double staining 
There are two techniques used to detect PrPSc proteins, using antibodies. In one 
technique, two different antibodies are used to stain two serial tissues segments side by 
side; one identifying the PrPSc and the other identifying the cellular structure (Noorden 
1986). However, this can sometimes lead to the risk of misidentifying a similar cellular 
structure as PrPSc. In the other method, two different antibodies are used in the same 
single tissue. This labeling technique requires a color coding to detect and differentiate 
the antigen of interest (Hancock, 1984). The major disadvantage with the immune-double 
staining method is the cross reaction of the antibodies during detection (Noorden 1986).  
2.7.3 Conformation-Dependent Immunoassay 
Initially, when Prusiner’s lab identified the TSE infectious agent prion, they 
developed a technique to inactivate the prions in the brain by using a protease enzyme, 
Proteinase K. It was determined that this prion protein is used for signal transduction 
inside the cell (Chesebro, 2003). The remaining protease resistant PrPSc after the 
proteolysis with Proteinase K enzyme will then react with the fluorescent coated antibody 
which enables its detection (Farquhar et al., 1989). However the major disadvantage with 
this protease was that a large amount of the infectious protein is also protease sensitive 
and is undetectable by the antibody. Due to this reason researchers were not able to 
conclude the exact amount of the infectious agent present.  
Farquhar and his group in 1989 developed a new technique which enables 
detection of the infectious agent for Scrapie and BSE at the post mortem stage. This uses 
a high affinity antibody that identifies the PrPSc by its structure. The infectious tissue 
extract is treated with the high affinity antibodies and its reactivity is measured at the 
17 
onset. The infectious agent is then treated with certain chemicals so that the protein gets 
unfolded and the unseen regions get exposed. This is then treated with antibodies and 
reactivity is measured. The degree in reactivity differs highly between the denatured 
protein and its native form and the ratio between the diseased native prion proteins to the 
denatured form gives the exact amount of PrPSc in the brain tissue (Farquhar et al., 1989). 
2.7.4 Western Blotting  
Western blotting is one of the major techniques used by researchers worldwide to 
detect proteins. This method uses a specific antibody for the protein of interest. Proteins 
are first separated based on molecular weight by the Sodium Dodecyl Sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to a nitrocellulose 
membrane or polyvinylidene difluoride (PVDF) membrane. The antigen or protein of 
interest is then detected using specific antibodies. The protein is bound to the specific 
antibody first and later this antibody is coupled with a secondary antibody labeled with a 
luminescent substrate for detection of the protein. Depending on the labeling of the 
secondary antibody, the detection methods can vary from chemiluminescence, staining, 
autoradiography and flurography. In the case of prion diseases, western blotting has been 
extensively used to identify both the PrPC and PrPSc where the proteins are detected as 
three separate bands on the blot: nonglycosylated, monoglycosylated and diglycosylated. 
Each of these has different molecular weights and based on their molecular weight 
pattern researchers are able to identify different strains of Scrapie (Thuring et al., 2002). 
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2.7.5 Mass Spectrometry  
This is a method used for studying the chemical structure of peptides and other 
molecules. This technique is based on the generation of charged molecules or fragments 
of molecules by ionizing chemical compounds. The measurement of mass to charge ratio 
enables the identification of the peptide. The mass to charge ratio of the peptides are 
calculated by the motion of the ions when they pass through the electromagnetic field. 
The Mass Spectrometry method can be used both quantitatively and qualitatively: which 
includes identification of unknown compounds, detection of its structure and 
determination of isotopic composition of molecules.  
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EXPRESSION AND DETECTION OF RECOMBINANT SHEEP PRION PROTEIN 
(RecShPrPC) USING HUMAN NEUROBLASTOMA CELLS AND  
WESTERN BLOTTING 
S.Prasad1, 2, U. DeSilva1, C. A. Mireles DeWitt1, 2 
1Department of Animal Science, Oklahoma State University, Stillwater, OK, 74075 
2 The Robert M Kerr Food and Agricultural Products Center, Oklahoma State University, 
Stillwater, OK, 74075 
ABSTRACT 
 
The objective of this study was to over express the sheep normal prion protein 
(RecShPrPc) in SK-N-SH cells using a mammalian expression vector with C-terminal 
6XHis-tag for large scale purification by Nickel-Nitrilotriacetate column 
chromatography. The full length prion open reading frame was PCR amplified and the 
complete coding sequence (PrP25-234) including the signal peptide from both C and N 
terminal ends of the protein was subcloned into pcDNA6.0 plasmid. The orientation and 
integrity of the cloned PCR product in the mammalian expression vector was confirmed 
by DNA sequencing. The prion gene was transfected using Lipofectamine2000 reagent 
and successfully over expressed in SK-N-SH cells. The cells were lysed and the over 
expressed prion protein was detected using Western Blot. Production of RecShPrPC using 
this method would ensure the availability of large amounts of this protein for further 
downstream applications. In vitro production of the full length PrPC and its detection is 
important in further studies aimed at deciphering the biochemistry and structure of prion 
proteins. 
Key Words: Expression, Fusion protein, His tag, Prions 
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INTRODUCTION 
The unique nature of the prion protein triggered the interest of researchers 
worldwide to study the molecular mechanisms underlying the cause of transmissible 
spongiform encephalopathies (Prusiner, 1994). Prions are infectious proteins that cause 
the neurodegenerative diseases in humans and animals. According to the ‘Protein only’ 
hypothesis (Prusiner, 1982) the conversion of normal PrPC to abnormal PrPSc is by post 
translational modification in its secondary structure (Pan et al., 1993, Weissmann, 1995). 
Although similar in its chemical properties, sensitivity to proteases, altered solubilities 
and different cellular distribution differentiate the normal PrPC from abnormal PrPSc 
(Prusiner, 1982, Stahl et al., 1993). To understand the biochemical principles and 
molecular mechanisms differentiating the PrPC from PrPSc, it is important to study the 
structural properties of both isoforms. Even though scientists attempted to extract and 
purify PrPC from tissues of various hosts, low expression and yield of the protein was 
always a limiting factor (Scott et al., 1988).  We expressed the entire open reading frame 
of sheep normal PrPC in a mammalian cell system fused with a hexa histidine tag at the C 
terminal end. The expressed protein was confirmed using western blotting and the 
purification of the protein was performed using nickel nitriloacetate purification system. 
Sheep prion protein was used in our study as they are safer to work with and is one of the 
more highly studied prion proteins. 
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MATERIALS AND METHODS 
Cloning the full length open reading frame of normal Sheep prion protein gene 
(ShPrPc) into Mammalian expression vector pcDNA 6.0 with His-tag 
Polymerase chain reaction (PCR) amplification of full length ovine prion gene: The 
ovine prion gene in the Zeroblunt vector was amplified by the PCR using the following 
oligonucloetide primers: forward 5’- TCGGATCCATGTGGAGTGACGTG-3’ and 
reverse 5’-CAGAATTCTCCTACTATGAGAAA -3’ obtained from Integrated DNA 
Technology (IDT). The PCR reaction was performed with 100ng of the plasmid DNA  
using Roche’s Fast start high fidelity PCR system (Cat # 3553426001; Indianapolis, IN) 
and the PCR conditions as follows: (1) Initial denaturation at 950 C for 2 min, (2) 
denaturation at 950 C for 30 seconds, (3) Annealing at 550 C for 30 seconds, (4) extension 
at 720 C for 1 min, (5) final extension at 720 C for 30 seconds, and steps (2) through (5) 
were repeated 30 times. The 790 bp PCR product was analyzed by 1.2% agarose gel 
electrophoresis for the confirmation of the quality of PCR. The gel was analyzed by an 
HR 6100 system, (UVP Gel Doc-IT Imaging system, Upland, CA). 
Expression construct: The mammalian expression vector pcDNA™6/myc-His A, B, & C 
was obtained from Invitrogen Corporation (Cat # V221-20; Carlsbad, CA), which has a 
6X histidine repeat at the C terminal which would help later in the purification of the 
protein. The plasmid was amplified using PCR and transformed following the 
manufacturer’s instructions and stored at -200 C.  
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Restriction digestion, Ligation and Transformation of the pcDNA 6/myc-His 
Mammalian expression vector into One shot TOP’10 competent cells. About 20ng 
each of the PCR amplified plasmid DNA of the full length ovine prion gene and the 
pcDNA 6/myc-His mammalian expression vector were digested using the EcoR1 and 
BamH1 restrictions enzymes (1/10 of total digest volume) obtained from New England 
Biolabs (Cat #s R0101 and R0136; Ipswich, MA). The treated plasmids were analyzed by 
1% agarose gel electrophoresis and gel purified using the Zymoclean™ Gel DNA 
Recovery Kit (Cat #D4001; Orange, CA) according to the manufacturer’s instructions. 
The extracted vector and the full length ovine prion gene were ligated and transformed 
following the manufacturer’s instructions using the Rapid Ligation and transformation kit 
from Fermentas (Cat #K1431; Glen Burnie, MD). Positive clones with the complete 
plasmid were identified by plasmid extraction and PCR following the above said 
conditions. The sequence of the isolated PrPC-6X His gene was confirmed by DNA 
sequence analysis using Applied Biosystems (Foster city, CA) Model ABI 3700 DNA 
analyzer at the DNA-Protein Core Facility at Oklahoma State University, Stillwater. 
Cell culture 
The mammalian cell line used for transfecting the full length mature ovine prion 
gene is the Human neuronal cells, also termed as SK-N-SH cells and was obtained from 
ATCC (Cat # HTB-11™; Manassas, VA). The cells were grown in RPMI 1640 culture 
medium supplemented with 10% fetal bovine serum, Penicillin and streptomycin (Cat # 
SV30010, Hyclone, Logan, UT) and Amphotericin B (Cat# SV 30078, Hyclone, Logan, 
UT) in a humidified atmosphere with 5% CO2 at 370 C as described in the ATCC’s 
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protocol with a few modifications. The cells were maintained by passaging them at 
regular intervals of 7 days or when attained 90% confluency (Masters and Stacey, 2007).  
Transfection of pcDNA 6/myc-His-full length ovine prion gene into SK-N-SH cells 
  Before transfection, the cells were divided into aliquots of 2 x 105 cells per mL 
(counted using a haemocytometer) in a 100mm culture dish. After 18-24 hour, the cells 
were transfected with pcDNA 6/myc-His-ovine prion gene by using Lipofectamine 2000 
reagent (Cat # 11668-027; Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocol. After 24 hour, cells were collected and analyzed for gene expression.  
SDS-PAGE and Western Blotting 
The whole cell lysate was prepared using the Mammalian Protein Prep Kit (Cat 
#37901; Qiagen, Valencia, CA) following the manufacturer’s protocol. The lysed cells 
were centrifuged at 5000 x g for 10 minutes and the supernatant was collected for 
SDS/PAGE and Western blot analysis. The samples were analyzed according to Laemmli 
(1970). The whole cell lysates were denatured in 2x SDS-laemmli buffer by boiling it for 
5 minutes at 950 C and were loaded into a 10% precast Tris-glycine gel obtained from 
Biorad (Cat #161-1101EDU; Hercules, CA) to do the electrophoresis using Biorad’s Mini 
Protean vertical electrophoresis system. Protein staining was performed by Coomassie 
Brilliant Blue staining (Laemmli, 1970). 
Western blotting was performed from the unstained SDS gel by transferring to a 
PVDF membrane using a Mini Trans Blot cell (Biorad Laboratories, Hercules, CA) for 1 
hour at 100 volts. The membrane was blocked using 5% Bovine serum albumin in Tris 
Buffer Saline (TBS) (20mM Tris and 500mM NaCl) for 1 hour and was incubated with 
the primary antibodies (1:3000) F89/160.1.5 (Cat # P6488; Sigma, St. Louis, MO) and 
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L42 (Santacruz  Biotechnology, CA) at 40 C for 1 hour. The membranes were washed 
three times, 5 minutes each in Tris Buffer Saline with 0.1% Tween-20 (TTBS) to remove 
any unbound primary antibody and incubated with the secondary antibody(1:5000), Goat 
anti-mouse IgG HRP conjugate (Cat# 170-6516 ,Biorad Laboratories, Hercules, CA). 
After thorough washing with TTBS, the labeled fusion protein was detected using the 
chemiluminesce in a VersadocTM Imaging Systems, (Biorad, Hercules, CA). The primary 
antibodies used in the study were monoclonal mouse anti prion IgG1 F89/160.1.5 which 
recognizes the IHFG amino acids of PrPC and PrPSc from a variety of species including 
sheep and L42 which recognizes the amino acids 145 to 163 in the prion protein gene.  
Purification of the RecShPrPC Using Ni-NTA Purification System 
Purification of the overexpressed protein samples from 2 x 105 cells per 1mL 
from a 100mm culture dish was performed under the denaturing conditions as described 
in the manufacturer’s instructions in Invitrogen’s Probond purification kit. The 
Guanidinium lysis buffer, pH 7.8 was equilibrated to 370 C and 3mM, 50mM and 
100mM Imidazole was added to it in respective tubes. The whole cell lysate was 
resuspended in 8 mL of the lysis buffer with protease inhibitor cocktail (Cat #37901; 
Qiagen, Valencia, CA) and the cells were mixed thoroughly at room temperature for 15-
20 minutes. The lysed cells were centrifuged at 7000 x g at 40 C. The supernatant was 
collected into a fresh tube and was purified on a Ni-NTA purification column (supplied 
with the kit). The protein was allowed to bind with 2mL of the Ni2+- nitriloacetate resin at 
room temperature for 30 minutes. The tip of the column was snapped off and the samples 
were collected as 1 mL fractions and saved at 40 C for SDS-PAGE analysis. The columns 
were washed with Denaturing binding buffer with 3mM, 50mM and 100mM Imidazole, 
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by resuspending the resin and incubating for 2 minutes. This step was repeated and the 
eluate was collected and stored at 40 C. The column was then washed with Denaturing 
Wash buffer with 3mM, 50mM and 100mM Imidazole, pH 6.0 and was repeated twice. 
The eluate was collected and stored at 40 C. The protein was eluted by adding Denaturing 
elution buffer, pH 4.0 and 100mM Tris-EDTA buffer in 1 mL fractions. The 
concentration was measured using a Nanodrop ND-1000 Spectrophotometer. All the 
fractions were concentrated by passing through a membrane filter with a cut-off 
molecular weight of 30kDa (Cat# UFC9 030 24, Millipore, Bedford, MA) and stored at -
800 C. All the purification steps were performed in both room temperature and 
refrigeration temperature. 
RESULTS AND DISCUSSION 
Meat and meat products contaminated with prions are a major concern to the food 
industries with regard to food safety (Kay, 2005). Multiple investigations have shown 
that BSE infection can occur in cattle due to exposure to prions present in the meat bone 
meal (MBM; (Taylor et al., 1997). Therefore, it is important to develop newer detection 
methods to identify the presence of both normal and abnormal isoforms of the prions in 
the animal and human food systems. As a first step, it is important to over express 
different isoforms of prion protein in various in vitro and in vivo systems and quantify 
and characterize their expression trends.  This, in turn, will also enable researchers to 
study the structure of the protein expressed in each biological system and develop newer 
detection methods suited to each system. Researchers have successfully constructed 
molecular models to study the protein structure of the PrPC and PrPSc using NMR 
techniques (Huang et al., 1996). However, due to the highly unstable nature of the PrPC 
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and difficulties in obtaining large amount of the protein from mammalian tissues, 
expression systems were developed (Baron et al., 1999).  
Initial attempts to overexpress the full prion protein using non denaturing 
conditions led to very low expression (Mehlhorn et al., 1996). Researchers attempted to 
over express only the functional part of prion gene and these experiments were successful 
in producing higher rate of gene expression and detection (Gasset et al., 1992, Zhang et 
al., 1995, Mehlhorn et al., 1996). A study by Scott and others stated that apart from 
bacterial expression system, cultured cell lines also lead to poor or low expression of 
PrPC (Scott et al., 1988). Other studies also reported the poor efficiency of mammalian 
cells in expressing the native and abnormal prions (Kocisko et al., 1994). However, later 
research led to the development of in vivo and in vitro tissue culture or cell culture 
models to produce larger amount of prion protein which can be used for biochemical and 
structural studies. It is also important to develop an expression system that can produce 
recombinant PrPC and PrPSc as it will help in the investigation of the role of prions in 
scrapie and other TSEs using molecular genetic techniques (Scott et al., 1992). Non 
neuronal cell lines capable of expressing the abnormal infectious form of prions have 
been reported previously where rabbit kidney epithelial cells were used to over express 
ovine prnp gene (Vilette et al., 2001).   
It is known that neuronal cells serve as good media for infectious prion over 
expression but non infectious full length sheep prion protein has not been over expressed 
in such a system. This study is one of the first efforts in this direction.  In this study, a 
Histidine tagged fusion system was used to overexpress the full length (residues 1-256) 
of ShPrPC with Human neuroblastoma cells (SK-N-SH). We subsequently conducted 
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experiments to detect the overexpressed RecShPrPC using Western blotting and DNA 
fingerprintng. Sheep prion protein (ShPrPC) was chosen in this study as it was one of the 
most studied and well defined among the prion proteins. It was also safer to work with 
from a safety standpoint as it highly differ in the sequences from humans and reduce the 
incidence of transmission of sheep prions to humans (Prusiner, 1989).  
Expression of the recombinant fusion protein His-PrPC into pcDNA 6/myc-His B 
Mammalian expression Vector 
 The entire ORF of the sheep prnp gene was previously cloned in our lab using 
Invitrogen’s Zero Blunt Vector (Figure 1). The His-PrPC was constructed by sub-cloning 
the sheep normal prion gene (790 bp) into the pcDNA 6/myc-His B mammalian 
expression vector (Figure 2). This vector codes for 5126 nucleotides, i.e. 1708 amino 
acids. The sheep PrPC sequence was inserted between the EcoR1 and BamH1 restriction 
sites with a downstream hexahistidine tag. This enables the purification of the fused 
recombinant protein by immobilized Ni-NTA chromatography column.  
The length and orientation of the subsequent clone (full length scrapie ORF in the 
mammalian expression vector) was confirmed by DNA Sequencing. The translation 
product of the cloned product was further confirmed to sheep prion protein using the 
SWISPROT, Geneva software. Also the molecular weight (Mw) of the resultant prion 
protein with the (His tag) was predicted to be 27 kDa (27887.4 Daltons) and the 
isoelectric point (pI) was theoretically projected to be 9.47.  
The histidine tagged full length scrapie prion gene was overexpressed in Human 
neuroblastoma cells (SK-N-SH) as described in the materials and methods. The resultant 
protein was solubilized and extracted using the mammalian lysis buffer using appropriate 
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protease inhibitors and nucleases. The cell lysate with the expressed proteins were 
separated from the debris by centrifuging the lysate for 15 minutes at 7000 x g. The 
whole cell lysate was analyzed for prion protein expression by SDS-PAGE and Western 
Blotting.   
SDS-PAGE and Western Blot 
The expressed gene from the SK-N-SH cells contained the sheep normal prion 
protein with two mobilities of 27kDa, 33kDa which are the unglycosylated and 
diglycosylated forms respectively as shown in the Coomassie blue staining of SDS-
PAGE (Figure 3). The proteins were identified after Western blotting by two monoclonal 
antibodies, mouse IgG F89/160.1.5 (Figure 4) and mouse IgG L42 against the prion 
protein (Figure 5). The expressed recombinant fusion prion protein had the 27kDa 
recombinant ShPrPC (1-256) as visualized in the Western blots with both the anti-prion 
antibodies. 
Purification of the Recombinant fusion protein (RecShPrPC) using Ni-NTA 
Purification system 
The full length PrPC was expressed in SK-N-SH cells and purification was 
attempted using the Nickel-Nitriloacetate purification system. The SK-N-SH cells were 
used to overexpress normal sheep prion protein and were solubilized using 6M 
guanidinium chloride along with protease inhibitors initially. The solubilized cell lysate 
was centrifuged at 7000 x g and the filtrate was loaded directly into a Ni-NTA 
purification column. The major fraction eluted should be His-PrPC when the pH was 
changed from 7.8 to 4.0. The eluted protein concentration was measured by Nanodrop 
ND1000 Spectrophotometer (Delaware, USA) and was determined to be 0.03mg/mL. As 
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this concentration was too low to be detected by western blotting, we tried several 
variations in the purification protocol. Changes were made in the pH of the elution buffer. 
The new pH tried was 3.5 instead of 4.0. Imidazole was used at varying concentrations 
(50 and 100mM) as a reducing agent based on previous studies in denaturing purification 
buffers. Some of these purifications yielded specific bands but of different molecular 
weight which were later identified as non- significant proteins by DNA fingerprinting 
performed at the DNA-Protein Core facility, Oklahoma State University. Repeated 
attempts using the native i.e. the non-denaturing conditions to purify the PrPC and 
subsequently using the denaturing conditions also yielded no positive results. Earlier 
studies by others have also shown that even under strong denaturing conditions the 
efficiency of purification was very low (Caughey et al., 1988, Scott et al., 1988, Turk et 
al., 1988, Pergami et al., 1996). 
Our original plan was to identify a mammalian expression system for the 
production of the native PrPC, and to develop a purification method to make the protein 
available in the pure form. We were successful in fulfilling the first objective. However, 
we were unsuccessful in purifying significant amounts of this over expressed protein, a 
problem faced by earlier researchers. The successful development of a protocol for the 
overexpression of sheep PrPC (ShPrPC) using the Human neuroblastoma cells was 
developed during the course of this study. This is the first human neuronal cell system 
used for expressing the sheep prion protein. Also literature and previous studies in our lab 
have shown that the Nickel affinity column chromatography is not a good method for the 
purification for the prion protein. This can be due to a multitude of reasons, singly or in 
combination, for example, incompatibility of the tag and low efficiency of the 
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components of the column can interfere with purification. Excessive amounts (2mL) of 
resin used can result in the overbinding of the nickel ions to the proteins. This can have 
an effect on the subsequent steps in the purification process. Use of lesser volume (100-
200 µL) of the resin or use of a two tag purification column where, the protein is 
denatured in the first system and then renatured to its original form using the second 
system might unravel the difficulties in purification. However, this study failed to 
identify the specific cause for this. 
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Figure Legends 
 
Figure 1: PCR product of the entire open reading frame of sheep PrPC in Zero Blunt 
vector ran on a 1% agarose gel. The PCR product was visualized by ethidium bromide 
staining. 
 
Figure 2: The PCR amplified product of the His-PrPC in pcDNA 6/myc-His B vector ran 
on a 1% agarose gel. The DNA bands were visualized by ethidium bromide staining. 
Lane 1 is the molecular weight marker ranging from 100 bp to 2000bp and lane 2 is the 
PCR product of the transformed His-PrPC in mammalian expression vector. 
 
Figure 3: SDS-PAGE analysis of the expressed RecShPrPC. Prestained molecular marker 
(lane 1), 40 µg each of the cell lysate with varying concentration of Lipofectamine 5 µL, 
10 µL and 20 µL were loaded onto lanes 2, 3 and 4. Lane 5 was the no target gene 
control. 
 
Figure 4: Western blot analysis using the Monoclonal antibody F89/160.1.5 from the 
whole lysate after tranfection of the fusion protein. 8 µg of the Prestained protein marker 
was loaded onto lane 1 and 40 µg each of the cell lysate with  varying concentration of 
Lipofectamine 5 µL, 10 µL and 20 µL were loaded onto lanes 2, 3 and 4. Control (No 
target gene) was loaded onto lanes 5 and 6 which show low expression.  
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Figure 5: Western blot analysis using the Monoclonal antibody L42 from the whole 
lysate after tranfection of the fusion protein. 8 µg of the prestained protein marker was 
loaded onto lane 1. 40 µg, 60 µg and 80 µg of the cell lysate were loaded onto lanes 2, 3 
and 4.  
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APPENDIX 1 
Preparation of 1.2% agarose gel 
1. Weigh 1.2 grams of agarose (Cat # A5304, Sigma, St.Louis, MO) and add it to 
100mL TBE buffer in an Erlenmeyer flask. 
2. Heat this mixture in a microwave approximately for 2 minutes, so that the agarose 
melts. Take caution that this doen not get boiled and spills over. 
3. Working under the hood, add 5µL of ethidium bromide (final concentration of 0.5 
µg/mL) (Cat # 7627, Sigma, St. Louis, MO) to the melted agar and mix gently by 
swirling it. (Note: Ethidium bromide is a carcinogen). 
4. Prepare the gel cast ready by taping both the ends to hold the melted agarose and 
pour the agarose to it. Place the comb and allow to set. 
 
10X TBE Buffer 
1. Tris Base (Cat # T4661, Sigma, St.Louis, MO) : 108 g 
2. Boric Acid     : 55 g 
3. EDTA (Cat # E7889 Sigma, St. Louis, MO) : 9.3 g 
4. ddH2O make up to    : 1 L 
Total volume     : 1 L 
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APPENDIX 2 
Polymerase Chain Reaction (PCR) 
1. Make the following recipe for the PCR mix 
ddH2O        : 14.5 µL 
PCR buffer (10x) with MgCl2    : 2.8   µL 
(Cat # E00007, Genscript, Piscataway, NJ) 
Forward primer (10mM)     : 0.4   µL 
Reverse primer (10mM)     : 0.4   µL 
dNTPs  (10mM)       : 0.4   µL 
(Cat # D0056, Genscript, Piscataway, NJ) 
Taq polymerase (2.25mM)     : 0.25 µL 
(Cat # E00007, Genscript, Piscataway, NJ) 
Plasmid DNA (100ng)     : 1.0   µL 
 
Total         : 20   µL 
2. Touch spin the PCR mix on table top centrifuge and place onto a thermocycler 
(MJ Research PTC-200 Thermal cycler, DNA engine, Ramsey, MN) with the 
following PCR conditions: 
i. Initial denaturation at 950 C for 2 minutes, 
ii. Denaturation at 950 C for 30 seconds, 
iii. Annealing at 550 C for 30 seconds, 
iv. Extension at 720 C for 1 minute.   
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v. Final Extension at 720 C for 30 seconds and repeat steps (ii to v) 30 
times. 
 
3. Upon completion of the PCR reaction, add 3 µL of 6X sample buffer (Cat# 161-
0767-EDU, Biorad Laboratories, Hercules, CA) to the PCR product and run on a 
1.2% agarose gel with ethidium bromide (final concentration 0.5µg/mL). 
4. Visualize the gel using an imaging system HR 6100 system, (UVP Gel Doc-IT 
Imaging system, Upland, CA) to analyze the PCR results. 
  
Diagram showing cloning the full length ovine prion gene onto pcDNA6/
mammalian expression Vector (Invitrogen, Carlsbad, CA)
 
50 
APPENDIX 3 
 
 
prnp gene  
myc/His 
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APPENDIX 4 
DNA sequence analysis of the entire prion gene ORF with C and N terminal 
signal peptides in Mammalian expression vector 
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Diagram showing cloning the full length ovine prnp gene onto pCR
Topo Vector (Invitrogen, Carlsbad, CA)
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APPENDIX 5 
 
 
 
- BLUNT II - 
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APPENDIX 6 
DNA sequence analysis of the entire prion gene ORF in Zero blunt vector 
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Cell culture of Human neuroblastoma 
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APPENDIX 7 
cells on Days one, three and nine
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Structures of normal and abnormal prion proteins
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APPENDIX 8 
 
(Ory Jillian, 2006) 
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APPENDIX 9 
Coding region of sheep (Ovis aries) prion protein 
MVKSHIGSWILVLFVAMWSDVGLCKKRPKPGGGWNTGGSRYPGQGSPGGNRYPPQGGGGWG
QPHGGGWGQPHGGGWGQPHGGGWGQPHGGGGWGQGGSHSQWNKPSKPKTNMKHVAGAAAA
GAVVGSLGGYMLGSAMSRPLIHFGNDYEDRYYRENMYRYPNQVYYRPVDQYSNQNNFVHDCV
NITVKXHTVTTTTKGENFTETDIKIMERVVEQMCITQYQRESQAYYQRGASVILFSSPPVILLISFLI
FLIVG (NCBI accession number P23907).  
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